XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue $ 9,207,586 $ 5,079,523 $ 20,482,742 $ 14,484,775
Cost of revenue 2,262,031 1,590,675 5,912,632 4,407,270
Gross profit 6,945,555 3,488,848 14,570,110 10,077,505
Operating expenses:        
Research and development 1,248,870 717,256 3,212,309 1,758,480
Selling, clinical and marketing 3,401,182 2,387,090 8,540,161 6,689,578
General and administrative 3,253,056 2,408,871 8,779,024 7,427,818
Total operating expenses 7,903,108 5,513,217 20,531,494 15,875,876
Loss from operations (957,553) (2,024,369) (5,961,384) (5,798,371)
Other (income) expense, net        
Interest income (76,020) (112,300) (318,555) (302,053)
Other expense, net 0 467 0 6,098
Loss on equity investment 0 70,124 0 99,840
Total other expense (income), net (76,020) (41,709) (318,555) (196,115)
Loss before income taxes (881,533) (1,982,660) (5,642,829) (5,602,256)
Income tax expense 84,876 46,356 280,819 85,204
Net loss $ (966,409) $ (2,029,016) $ (5,923,648) $ (5,687,461)
Weighted average number of common shares outstanding:        
Basic 37,950,515 35,266,361 37,359,366 27,537,357
Diluted 37,950,515 35,266,361 37,359,366 27,537,357
Net loss per share attributable to common stockholders        
Basic $ (0.03) $ (0.06) $ (0.16) $ (0.21)
Diluted $ (0.03) $ (0.06) $ (0.16) $ (0.21)
Product revenue        
Revenue $ 9,207,586 $ 5,029,523 $ 20,482,742 $ 12,719,855
License revenue        
Revenue $ 0 $ 50,000 $ 0 $ 1,764,920